Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine

Giuseppe Derosa, Roberto Mereu, Sibilla A T Salvadeo, Angela D'Angelo, Leonardina Ciccarelli, Mario N. Piccini, Ilaria Ferrari, Alessia Gravina, Pamela Maffioli, Arrigo F G Cicero

Research output: Contribution to journalArticlepeer-review


Objective: Metformin is the drug of choice to treat obese type 2 diabetes patients because it reduces either insulin-resistance and body weight. We aimed to comparatively test the efficacy and tolerability of pioglitazone and sibutramine in metformin-intolerant obese type 2 diabetic patients treated with sibutramine. Materials and Methods: Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day). All intolerant patients to metformin received a treatment with pioglitazone (45 mg/day) and sibutramine (10 mg/day) and they were compared with fifty-three patients treated with metformin (3,000 mg/day) and sibutramine (10 mg/day) for 6 months in a single-blind controlled trial. We assessed body mass index, waist circumference, glycated hemoglobin, Fasting Plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, lipid profile, systolic blood pressure, diastolic blood pressure and heart rate at baseline and after 3, and 6 months. Results: No body mass index change was observed at 3, and 6 months in pioglitazone + sibutramine group, while a significant reduction of body mass index and waist circumference was observed after 6 months in metformin + sibutramine group (p

Original languageEnglish
Pages (from-to)265-271
Number of pages7
JournalInternal Medicine
Issue number5
Publication statusPublished - 2009


  • Intolerance
  • Metformin
  • Pioglitazone
  • Sibutramine
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)


Dive into the research topics of 'Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine'. Together they form a unique fingerprint.

Cite this